More on ABBV
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $150.57 |
|
|||
| Open | $149.52 | ||||
| 52 Wk High | $68.12 | ||||
| 52 Wk Low | $50.71 | ||||
| Day High | $150.05 | ||||
| Day Low | $147.75 | ||||
| P/E | 32.54 | ||||
| EPS | $4.61 | ||||
| Volume | 8,404,969 | ||||
- AbbVie (ABBV) Announces Publication from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib
- The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
- The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
- Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- Form 4 AbbVie Inc. For: May 23 Filed by: SEVERINO MICHAEL
- AbbVie to Present at the Bernstein 38th Annual Strategic Decisions Conference
- AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lucid, AbbVie, Playstudios, and IBM and Encourages Investors to Contact the Firm
- AbbVie (ABBV) Reports Positive Data from Phase 3 Study of Cariprazine
Entities mentioned with ABBV
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Dividend | View Related Stories »
- Morgan Stanley | View Related Stories »
- Options | View Related Stories »
- Goldman Sachs | View Related Stories »
- Show More...
